Synapse - Karissa Whiting

Results (50)

Magnetic resonance imaging (MRI) radiomics as predictor of clinical outcomes to neoadjuvant immunotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy

Meeting Abstract

Necchi, A.; Brembilla, G.; Arita, Y.; Akin, O.; Apte, A.; Cosenza, M.; Maiorano, B.; Tateo, V.; Cigliola, A.; Mercinelli, C.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma

Meeting Abstract

Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Circulating tumor DNA and response to cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma enrolled in CALGB 90601 (Alliance)

Journal Article

Guercio, B. J.; Whiting, K.; Shah, R. H.; Ballman, K. V.; Halabi, S.; Regazzi, A. M.; Milbank, J. H.; Bajorin, D. F.; Beltran, H.; Morris, M. J.; more...
European Urology Open Science (2025)

Fulltext@MSK | Save

Correlative science from a phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)

Meeting Abstract

Bochner, B. H.; Alam, S. M.; Blanchard, L.; Yao, N.; Angulo-Lozano, J.; Wong, J.; Knorr, D.; Whiting, K.; Seshan, V.; Donahue, T.; more...
Urologic Oncology: Seminars and Original Investigations (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Molecular, immunohistochemical and clinical determinants of urothelial carcinoma of the bladder with nested subtype

Meeting Abstract

Koll, F. J.; Basar, M.; Chen, Z.; Tin, A. L.; Alam, S. M.; Tallman, J. E.; Clinton, T. N.; Whiting, K.; Chen, J. F.; Sarungbam, J.; more...
European Urology (2024)

Fulltext@MSK | Save

Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)

Meeting Abstract

Gupta, A.; Whiting, K.; Keegan, N. M.; Schmalz, J.; Al-Ahmadie, H. A.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Iyer, G.; Rosenberg, J. E.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Differential NEUROD1, ASCL1, and POU2F3 expression defines molecular subsets of bladder small cell/neuroendocrine carcinoma with prognostic implications